about
HER 2/neu protein expression in colorectal cancerEarly prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activityB cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancerIntermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer.Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis.Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma.Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastasesPerioperative Non-Invasive Indocyanine Green-Clearance Testing to Predict Postoperative Outcome after Liver Resection.Side effects during chemotherapy predict tumour response in advanced colorectal cancerSurgery for liver metastases originating from sarcoma-case series.The role of biological agents in the resection of colorectal liver metastases.Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.Bivalent role of Intra-Platelet Serotonin in Liver Regeneration and Tumor Recurrence in Humans.Long-term outcomes of patients with 10 or more colorectal liver metastases.Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983.Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection.Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis.Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.Immunological risk factors are solely responsible for primary non-function of renal allografts.Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis.Urgent need for a new staging system in advanced colorectal cancer.Perioperative Von Willebrand Factor Dynamics are Associated with Liver Regeneration and Predict Outcome after Liver Resection.Hepatic steatosis assessment with 1H-spectroscopy and chemical shift imaging at 3.0 T before hepatic surgery: reliable enough for making clinical decisions?Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on GastrointesValue of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma.PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).IMPROVEMENT OF CARDIAC OUTPUT AND LIVER BLOOD FLOW AND REDUCTION OF PULMONARY VASCULAR RESISTANCE BY INTRAVENOUS INFUSION OF l-ARGININE DURING THE EARLY REPERFUSION PERIOD IN PIG LIVER TRANSPLANTATION1Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first?Elevated ADAMTS13 Activity is Associated with Poor Postoperative Outcome in Patients Undergoing Liver ResectionIt is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients
P50
Q33242725-3E964993-33FB-4687-AD91-6227CD4DC726Q33562780-C0388859-CAB7-4116-829D-885E330958E6Q33721433-4F273235-84A7-46EA-B821-F3FBBFA647FEQ34413691-1C0D61F3-0A63-4B7F-B174-1961B0203A98Q34625619-454779DA-3CE1-4CAB-AB73-61257116A569Q34660081-A336CCCD-DFF4-4C58-B96C-4B2429E162BFQ35577684-DA235120-D863-4EBA-B597-12428068CCE6Q35637857-8AB9F8BF-DB6D-440A-8270-1ED6E6EAB6DAQ35669106-5588B1A4-5079-4895-B79C-933A24B0C9D1Q35879070-7BA9C77C-2B17-43FB-A270-7ED82B8557BFQ36182148-4AD43774-59B2-4EF0-A1D6-85C12CB5529DQ36615421-FE68A5F2-6D54-4872-A4F7-72FB44EC6E95Q37899078-E5FE6B95-D830-435A-A4F6-99FC1D20E467Q38026152-1B044630-1DA4-4109-92F1-B423DBB419F7Q38299712-BA873728-0B57-49A3-95E8-0CD93453EBFEQ38371655-49855F99-76F2-43FE-AE10-E459B1D93866Q38669762-4851D155-6BFE-41B2-8174-9384D3F72D03Q39275325-D485A827-FD3E-4074-BB8E-42D9918D4FDEQ39479370-CEF6431D-41CF-457D-BDCB-B9B835A5B3BCQ40193396-B04F27E5-95E4-4BE2-B2DE-781DFE9E9112Q40243471-6594FC67-56B9-4E11-8C95-4D92A073FC11Q41265675-2DD1E6ED-6F6D-450C-BFFF-257E1C752001Q44548792-CC75D771-92F0-4C10-BCBB-592AF5052FDDQ45033369-872CB200-43DB-4608-9321-61DDDEF9E7E4Q46008336-49EAE2FF-C922-4559-ADF8-19E0D2B9A323Q46311333-CAE8CE31-9F30-4132-A41A-715E8EC20715Q46423656-2A82AE50-4F31-4BEF-9C67-49799BB03AD8Q48300441-0C6B54CA-67EB-45B1-9784-9CA2A2CC0CD5Q49119627-E8AFAB8B-78E2-48D1-9D9A-051DA604AC20Q50077151-7EE46AB1-B0F5-437D-8DD6-E868DE0D87F8Q50999716-B7F68D8A-B397-4FEA-BD45-555B387633EDQ51184879-17F0B6CA-6A23-44CB-9A31-B906DCE71177Q51530246-023BB28A-3B0D-49B6-9829-2CC99AE264ADQ52861120-6C6DBC9D-276D-413E-BF9A-49A3BFDEFF9EQ53355472-5E9E2762-306A-40E4-830F-F012C590EF99Q53388486-A4BB676B-BF42-462A-929D-7D5B2981E29FQ58232932-72711C97-123C-4AE8-9FDC-39F7A5CDBCA8Q58797711-A747A059-1C46-4B98-BD90-4907C7579178Q59127036-13DB685F-D7C2-4CEA-92D4-95B101EC14C6Q59616911-FBEE0EE5-DC74-42AA-B864-AE9C55B33B05
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
T Gruenberger
@ast
T Gruenberger
@en
T Gruenberger
@es
T Gruenberger
@nl
type
label
T Gruenberger
@ast
T Gruenberger
@en
T Gruenberger
@es
T Gruenberger
@nl
prefLabel
T Gruenberger
@ast
T Gruenberger
@en
T Gruenberger
@es
T Gruenberger
@nl
P1153
6603768510
P31
P496
0000-0002-2671-0540